1. Epidemiology Working Group for Ncip Epidemic Response. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. (In Chinese)]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145–151.

2. CDC. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 – United States, February 12 − March 28, 2020. MMWR. 2020;69(13):382–386.

3. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020.

4. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes MetabSyndr. 2020;14(4):303-310.

5. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disea­ se in COVID-19 pneumonia – a systematic review, metaanalysis, and meta-regression. Diabetes MetabSyndr. 2020; 14(4):395–403.

6. Daousi C, Casson IF, Gill GV, et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006;82(966):280–284.

7. Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 – COVID-NET, 14 states, march 1-30, 2020. MMWR Morb Mortal WklyRep. 2020;69(15):458-464.

8. Hales SM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief No. 360, February 2020.

9. Simmonet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) 2020. Avalable from:

10. Korkushko O. V., CHebotarev D. F., CHebotarev N. D. Vozrastnye izmeneniya dyhatel‘noj sistemy pri starenii i ih rol‘ v razvitii bronholegochnoj patologii. Ukraїns‘kijpul‘monologіchnij zhurnal. 2005, № 3 (dodatok) s. 35–41.

11. Kolchinskaya A. Z. Nedostatok kisloroda i vozrast. – K.: Nauk, dumka, 1964. – 336 s.

12. YAshina L. A., Ishchuk S. G. Izbytochnaya massa tela, ozhirenie i patologiya lyogkih: vzglyad pul‘monologa. Pul‘monologiya. Poglyadfahivcya. Zdorov!ya Ukraini. Kviten‘. 2011. S. 14–15.

13. Burlakova E. B., Arhipova G. V., Goloshchapov A. N. Membrannye lipidy kak perenoschiki informacii. Bioantiokisliteli v regulyacii metabolizma v norme i patologii. M., 1982, s. 21–37.

14. Medicinskaya nauka Armenii NAN RA t. LIII ¹ 4 2013 UDK 577.15:616.24 Lipidy i ih rol‘ v razvitii legochnyh zabolevanij L. G. Simonyan Kafedra terapii № 3 EGMU im. M. Geraci. Erevan.

15. Patologicheskaya anatomiya COVID-19. Pod obshchej redakciej O. V. Zajrat‘yanca., M. 2020.

16. Rybakova M. G. Patologicheskaya anatomiya novoj koronavirusnoj infekcii COVID-19. Pervye vpechatleniya. ZHurnal: Arhiv patologii. 2020;82(5): 5–15

17. Torbicki A., Perrier A., Konstantinides S. et al. Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) // European Heart Journal. 2008. Aug. V. 29, № 18. P. 2276–2315. doi: 10.1093/eurheartj/ehn310. Epub. 2008. Aug. 30.

18. Feigin DS. Improving specificity of computed tomography in diagnosis of malignant mediastinal lymph nodes / [Feigin DS et al.] // J ComputTomogr. № 9. – 1985. S. 21–32.

19. Baranov V. G. Rukovodstvo po endokrinologii. L. Medicina. 1977.

20. Balabolkin M. I. Endokrinologiya.M., «Universum pablishing», 1998.

21. Mohort T. V., Zabarovskaya Z. V., SHepel‘kevich A. P. Kinicheskaya endokrinologiya. Minsk. «Vyshejshaya shkola». 2013.

22. Lobanova M. V. Komatoznye sostoyaniya pri saharnom diabete. Minsk. «Belprint». 2014.